32 Results

People

  1. Riely
    Riely
  2. Kris
    Kris
  3. Ladanyi
    Ladanyi
  4. Berger
    Berger
  5. Miller
    Miller
  6. Solit
    Solit
  7. Arbour
    Arbour
  8. Pao
    Pao
  9. Schultz
    Schultz
  10. De Stanchina
    De Stanchina

Groups

  1. Department of Medicine (32)
  2. Solid Tumor Oncology Division (32)
  3. Thoracic Oncology (32)
  4. GSK Faculty (18)
  5. Human Oncology and Pathogenesis Program (17)
  6. Tow Center for Developmental Oncology (TCDO) (12)
  7. Sloan Kettering Institute Postdocs (9)
  8. Biostatistics Service (8)
  9. Epidemiology and Biostatistics (8)
  10. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (6)
  1. "genetics"
  2. "Gregory Riely"
Formats
  1. Journal Article (29)
  2. Review (2)
  3. Guidelines (1)
Groups
  1. Department of Medicine (32)
  2. Solid Tumor Oncology Division (32)
  3. Thoracic Oncology (32)
  4. GSK Faculty (18)
  5. Human Oncology and Pathogenesis Program (17)
  6. Tow Center for Developmental Oncology (TCDO) (12)

More Groups

People
  1. Gregory Riely (32)
  2. Marc Ladanyi (12)
  3. Mark Kris (9)
  4. David Solit (6)
  5. Michael Berger (6)
  6. Vincent Miller (6)

More People

Years
  1. 2024 (2)
  2. 2023 (9)
  3. 2022 (6)
  4. 2019 (1)
  5. 2018 (1)
  6. 2017 (3)

More Years

Publications
  1. Clinical Cancer Research (7)
  2. Journal of Clinical Oncology (4)
  3. Journal of the National Comprehensive Cancer Network (3)
  4. Cancer Discovery (2)
  5. Journal of Thoracic Oncology (2)
  6. Nature Medicine (2)

More Publications

Publishers
  1. American Association for Cancer Research (13)
  2. American Society of Clinical Oncology (4)
  3. Harborside Press (3)
  4. Nature Publishing Group (3)
  5. Elsevier Inc. (2)
  6. American Medical Association (1)

More Publishers

Results (32)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • MIG6 mediates adaptive and acquired resistance to ALK/ROS1 fusion kinase inhibition through EGFT bypass signaling
    Journal Article

    Chen, N.; Tyler, L. C.; Le, A. T.; Welsh, E. A.; Fang, B.; Elliott, A.; Davies, K. D.; Danhorn, T.; Riely, G. J.; Ladanyi, M.; more...
    Molecular Cancer Therapeutics (2024)

    Fulltext@MSK | Save
  • Effects of KRAS genetic interactions on outcomes in cancers of the lung, pancreas, and colorectum
    Journal Article

    Grabski, I. N.; Heymach, J. V.; Kehl, K. L.; Kopetz, S.; Lau, K. S.; Riely, G. J.; Schrag, D.; Yaeger, R.; Irizarry, R. A.; Haigis, K. M.
    Cancer Epidemiology Biomarkers and Prevention (2024)

    Fulltext@MSK | Save
  • Clinical and molecular features of long-term response to immune checkpoint inhibitors in patients with advanced non–small cell lung cancer
    Journal Article

    Thummalapalli, R.; Ricciuti, B.; Bandlamudi, C.; Muldoon, D.; Rizvi, H.; Elkrief, A.; Luo, J.; Alessi, J. V.; Pecci, F.; Lamberti, G.; more...
    Clinical Cancer Research (2023)

    Fulltext@MSK | Save
  • The GENIE BPC NSCLC cohort: A real-world repository integrating standardized clinical and genomic data for 1,846 patients with non-small cell lung cancer
    Journal Article

    Choudhury, N. J.; Lavery, J. A.; Brown, S.; de Bruijn, I.; Jee, J.; Tran, T. N.; Rizvi, H.; Arbour, K. C.; Whiting, K.; Shen, R.; more...
    Clinical Cancer Research (2023)

    Fulltext@MSK | Save
  • Combination therapy with MDM2 and MEK inhibitors is effective in patient-derived models of lung adenocarcinoma with concurrent oncogenic drivers and MDM2 amplification
    Journal Article

    Elkrief, A.; Odintsov, I.; Markov, V.; Caeser, R.; Sobczuk, P.; Tischfield, S. E.; Bhanot, U.; Vanderbilt, C. M.; Cheng, E. H.; Drilon, A.; more...
    Journal of Thoracic Oncology (2023)

    Fulltext@MSK | Save
  • Early changes in circulating cell-free KRAS G12C predict response to adagrasib in KRAS mutant non-small cell lung cancer patients
    Journal Article

    Paweletz, C. P.; Heavey, G. A.; Kuang, Y.; Durlacher, E.; Kheoh, T.; Chao, R. C.; Spira, A. I.; Leventakos, K.; Johnson, M. L.; Ou, S. H. I.; more...
    Clinical Cancer Research (2023)

    Fulltext@MSK | Save
  • Phase II, open-label study of encorafenib plus binimetinib in patients with BRAF(V600)-mutant metastatic non-small-cell lung cancer
    Journal Article

    Riely, G. J.; Smit, E. F.; Ahn, M. J.; Felip, E.; Ramalingam, S. S.; Tsao, A.; Johnson, M.; Gelsomino, F.; Esper, R.; Nadal, E.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Genomic mapping of metastatic organotropism in lung adenocarcinoma
    Journal Article

    Lengel, H. B.; Mastrogiacomo, B.; Connolly, J. G.; Tan, K. S.; Liu, Y.; Fick, C. N.; Dunne, E. G.; He, D.; Lankadasari, M. B.; Satravada, B. A.; more...
    Cancer Cell (2023)

    Fulltext@MSK | Save
  • Brief report: Combination of osimertinib and dacomitinib to mitigate primary and acquired resistance in EGFR-mutant lung adenocarcinomas
    Journal Article

    Elkrief, A.; Makhnin, A.; Moses, K. A.; Ahn, L. S.; Preeshagul, I. R.; Iqbal, A. N.; Hayes, S. A.; Plodkowski, A. J.; Paik, P. K.; Ladanyi, M.; more...
    Clinical Cancer Research (2023)

    Fulltext@MSK | Save
  • Characterization and management of adverse events observed with mobocertinib (TAK-788) treatment for EGFR exon 20 insertion–positive non–small cell lung cancer
    Review

    Yang, J. C. H.; Zhou, C.; Jänne, P. A.; Ramalingam, S. S.; Kim, T. M.; Riely, G. J.; Spira, A. I.; Piotrowska, Z.; Mekhail, T.; Garcia Campelo, M. R.; more...
    Expert Review of Anticancer Therapy (2023)

    Fulltext@MSK | Save